Diet and exercise appeared to improve asthma symptom control, overall fitness, and quality of life.
Researchers examined the efficacy of tezepelumab, a human monoclonal antibody, in treating moderate to severe asthma with non-eosinophilic inflammation.
Patients with COPD and comorbid cardiovascular disease may benefit from statin treatment depending on their C - reactive protein levels.
After accounting for individual risk factors, living altitude is not associated with variability in COPD prevalence.
Underlying cystic fibrosis may be a risk factor for the prediction of delayed gastric emptying in patients who undergo lung transplantation.
Pediatric patients with asthma are at the highest risk for adverse drug events, particularly with inhaled corticosteroids.
Two phase 3 clinical trials examined mepolizumab 100 or 300 mg vs placebo to treat moderate-to-severe COPD exacerbations.
Oral corticosteroids did not reduce symptom severity or duration in patients with lower respiratory tract infections without asthma.
Researchers hypothosized that increased sputum Gammaproteobacteria:Firmicutes ratio may serve as a biomarker to guide antibiotic treatment in COPD.
Advanced emphysema may benefit from endoscopic lung reduction treatment.
People with COPD have been found to benefit from statin therapies, with reduced risk of all-cause and pulmonary-related mortality.
Patients with COPD treated with mucolytic agents for at least 1 year were better protected against exacerbations compared with patients treated with placebo.
Adults with asthma benefit from tailoring interventions based on sputum eosinophils vs clinical symptoms.
Researchers analyzed over 2.1 million patient-years' worth of data to determine the impact of short-acting beta agonist use in asthma.
Participants received 70 mg of tezepelumab every 4 weeks throughout the study.
FEV1 was higher in patients who received tiotropium therapy vs those in the placebo group.
International trends in asthma mortality are useful for assessing the effect of treatment strategies on the burden of asthma.
A 2015 update from the 1990 Global Burden of Disease study reveals current prevalence and mortality of asthma and chronic obstructive pulmonary disease.
A new algorithm developed by the National Institute for Health and Care Excellence was not useful for diagnosing asthma in children and adolescents.
The pathogeneses of steroid insensitivity in severe, steroid-resistant asthma may unlock new potential treatments.
Asthma is associated with development of inflammatory bowel disease.
Fluticasone furoate and vilanterol combination therapy reduced both daytime and nighttime symptoms in patients with persistent uncontrolled asthma.
Study results showed the benefit of single-inhaler triple therapy vs ICS/LABA therapy in COPD.
Recent research suggests that perioperative and postoperative pulmonary rehabilitation improves outcomes in patients undergoing thoracic surgery.
Inhaled corticosteroids for COPD does not increase the risk for fractures when used for short-term periods.
Elevated sputum eosinophil levels correlate with the severity of clinical outcomes in asthma.
A single-center study found that omalizumab led to reductions in allergic response much earlier than previously demonstrated.
Influenza vaccination provided a small protective effect in patients with asthma.
Lower microbial diversity in the respiratory tract in patients with cystic fibrosis was linked with prophylactic antibiotics and less airway inflammation.
Pneumonia primarily affects young children, smokers, adults 65 years and older, and people with COPD.
Occupational exposures are a modifiable risk factor for COPD.
In children with allergic asthma and rhinitis, sublingual immunotherapy (SLIT) was shown to not only improve patient-reported symptoms, but also airway inflammation and pulmonary function.
Study outcomes provided insufficient evidence to support vitamin D supplementation for the prevention of atopy.
When pregnant women are exposed to certain air pollutants, the susceptibility to allergic asthma may increase across generations.
Moderate and severe asthma exacerbations were predictive of similar future events, and they appear to be phenotypically distinct conditions.
Researchers examined structural social support indicators, including living status, having a partner, number of close friends and relatives, and the presence of a family caregiver.
Allergic and nonallergic rhinitis guidelines include the latest updates from BSACI for diagnosing and managing children and adults.
When general practitioners refer patients to asthma diagnostic consultation services asthma diagnosis improved.
Cardio- and cerebrovascular events were more common in patients being treated with combination long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) therapies vs LABA/inhaled corticosteroids.
Comparative measures of inspiratory vs expiratory volumes show a penumbra of lung tissue at higher risk of damage from existing COPD.
The first study of antibiotic use in outpatients with COPD exacerbations found that doxycycline plus prednisone did not prolong the time between exacerbations.
Sweat chloride can predict severity in patients with CF, especially for long-term lung damage.
Intense exposure over the course of a single day has been linked to an elevated risk of developing chronic health conditions.
A study of 65 patients examined the efficacy of using serum periostin as a biomarker for asthma with comorbid upper airway disease.
Data were collected from 8956 mother-child pairs with children born between 1991 and 1992.
Azithromycin reduced exacerbations and improved quality of life in adults with asthma in a randomized double-blind placebo-controlled trial.
BMI is causally related to higher prevalence of asthma, but not hay fever or allergy.
Pro-inflammatory pathways associated with asthma reduce sepsis and sepsis related mortality in patients with infection.
Combination lumacaftor/ivacaftor therapy was found to be safe and effective in patients with cystic fibrosis aged 6 to 11 years.
Azithromycin therapy is more effective at preventing COPD exacerbations among patients with Helicobacter pylori infection than among those who are H pylori seronegative.
The patient presented with obesity and reduction in bilateral hip flexion strength and shoulder abduction.
Statin therapy reduces inflammation and improves quality of life in patients with severe bronchiectasis infected with P aeruginosa.
Higher doses were independently linked to slower change in emphysema, especially among former smokers
Two phase 3 clinical development programs showed improved breathing in children and adolescents with moderate-to-severe asthma regardless of allergic status.
Multiple studies presented at ATS 2017 indicated that indacaterol/glycoptrrolate inhaler therapy results in clinically significant improvements in COPD-related quality of life.
No difference was noted in all-cause readmission rates in the intervention vs non-intervention groups.
Testosterone blocks production of innate lymphoid cells, possibly explaining the gender disparity in asthma diagnoses.
A combination of several factors -- including electrical activity, high humidity, and rainfall -- can lead to asthma outbreaks in conjunction with thunderstorms.
Asthma risk increased when mothers required antidiabetic medication during pregnancy to manage either type 2 or gestational diabetes.
The most recent ERS guideline includes significant changes from prior recommendations in an effort to accommodate newer delivery devices.
The rise in asthma and allergy symptoms may be due to climate change which heightens the damage of airway cells by outdoor fungus.
The release of a new autonomous approach for terminating the COPD crisis has been lead by the National Heart, Lung and Blood Institute (NHLBI).
Treatment with full-dose angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers was found to slow disease progression in patients with emphysema.
Mepolizumab resulted in longer remission periods with a larger proportion of participants in remission compared to the placebo, which resulted in reduced glucocorticoid use.
Sublingual immunotherapy is associated with slower AR progression and less frequent asthma onset in patients with allergic rhinitis.
Researchers examined the relationship between COPD and right and left ventricular morphometry to determine which patients may better respond to beta-blocker therapies.
Online pulmonary rehabilitation is non-inferior to face-to-face rehabilitation for patients with COPD, according to research presented at ATS 2017.
Prenatal exposure to ambient fine particulate matter and stress are linked to increased childhood asthma in boys by age 6 years.
Imatinib demonstrated an improvement in mast-cell activity and airway hyperresponsiveness in severe refractory asthma vs placebo.
Researchers compared 4- and 8-week benralizumab vs placebo for asthma.
Oxidative stress may play an important role in the development of recurrent wheezing following viral ARIs in infancy.
A new survey shows that home oxygen services create barriers for patients with lung disease.
Data from the Generation R, SEATON, PACMAN, and BREATHE studies were analyzed to determine the link between asthma, asthma exacerbations, and childhood antibiotic use.
Compared to the year prior to bronchial thermoplasty (BT) treatment, in the 2 years after BT treatment, patients experienced reduction in severe exacerbations, hospitalizations, and ER visits.
More than 4 million women were included in an examination of the relationship between asthma and polycystic ovary syndrome.
Five studies collaboratively funded by the NIEHS, NHLBI, and NIAID explore ways of preventing and treating asthma.
The FDA has expanded the approved indication of ivacaftor for cystic fibrosis, increasing the number of rare gene mutations the drug may be used to treat.
The TRINITY study reports the significant benefits to extafine triple therapy taken in a single inhaler compared with tiotropium in chronic obstructive pulmonary disease.
Simulated studies were key to the approval of roflumilast for reducing COPD exacerbations.
A new study found no risks for exacerbation of asthma in children given LAIV, despite ACIP recommendations against its use in children with asthma.
Mepolizumab showed early and sustained clinically relevant improvements in quality of life, with a good safety profile in severe eosinophilic asthma.
Patients with COPD and asthma can be characterized by the presence of allergies and more exacerbation with less eosinophilic inflammation.
Study results suggest that gas trapping, not emphysema, is associated with pulmonary vascular remodeling in COPD.
The association between asthma and Rheumatoid arthritis can help identify high-risk patients and improve treatment options.
Combination therapy with an inhaled LABA and inhaled corticosteroid did not affect all-cause mortality in patients with COPD compared with inhaled placebo, LABA alone, or corticosterioid alone.
Treatment with antiasthma and antihistamine medication may help reduce migraine in this population.
Patients with asthma have an increased risk of pneumonia when using inhaled corticosteroids, including budesonide and fluticasone.
Oral corticosteroids, regardless of dose or duration, may increase the risk of adverse effects in patients with severe asthma.
Sunovion announces Utibron Neohaler, an inhalation powder for the long term maintenance treatment of airflow obstruction in COPD patients.
Inpatient antibiotic therapy is associated with greater likelihood of recovery following acute lung function decline in pediatric patients with cystic fibrosis.
The European Respiratory Society and the American Thoracic Society released clinical guidelines for the treatment of patients with chronic obstructive pulmonary disease exacerbations.
Noninvasive positive-pressure ventilation to clear secretions in patients with acute exacerbations of chronic obstructive pulmonary disease may be more beneficial than conventional mechanical ventilation.
Statin use was associated with a 20% lower risk for all-cause mortality and a 45% lower risk for pulmonary-related mortality.
Patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) had decreased exacerbations after 3 months of commencing budesonide/formoterol treatment.
The 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report was released and includes updated recommendations for the diagnosis and management of chronic obstructive pulmonary disease.
Researchers have suggested a new definition for common smoke-related pulmonary disease (CSPD).
Long-term supplemental oxygen does not provide any benefit for patients with stable chronic obstructive pulmonary disease regarding time of death or first hospitalization.
Study patients with late-onset asthma were 57% more likely to experience stroke, heart failure, myocardial infarction, or other CVD-related death.
In patients studied, 23% of patients with herpes zoster also had a history of asthma.